Sign inJoin
Company / Finance

Alpha Cognition Inc.

ACOG · NASDAQ

Alpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, supply risk, customer concentration, and control weaknesses take over.

FollowAdd to WatchlistAsk Question
NASDAQACOGCoverage BootstrapBiopharmaAlzheimer's DiseaseCommercial Launch
Latest ReportMay 13, 2026ACOG: the Alzheimer pill launch racing payer math and a cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.

Sign in as admin